A Pancreatic Cancer Pill Made Tumors Vanish in 1 in 12 Patients: The Psychology of Hope After Hopeless News

A Pancreatic Cancer Pill Made Tumors Vanish in 1 in 12 Patients: The Psychology of Hope After Hopeless News

Reviewed by a Psychology Postgraduate (MA)

The pancreatic cancer drug daraxonrasib made tumors shrink or disappear in 60.7% of patients in a small new trial, and in 1 in 12 they could no longer be seen on scans at all. For families who have learned to expect the worst news about pancreatic cancer, a headline like that lands like a door opening in a room that had no doors.

The short answer: Daraxonrasib with chemotherapy shrank tumors in 60.7% of 61 patients with metastatic pancreatic cancer in an early-phase trial presented on 20 November 2026, with tumors disappearing in 8.2%. Encouraging, but the study was small and not randomized, so a larger phase 3 trial must still confirm it beats chemotherapy alone.

What Happened in Barcelona on 20 November 2026?

What happened in Barcelona on 20 November 2026? Updated results from the RMC-GI-102 phase I/II trial were presented on 20 November 2026 at the EORTC-NCI-AACR Symposium in Barcelona by Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, and reported by ecancer and OncLive.

The trial tested daraxonrasib, brand name Rasonque, made by Revolution Medicines, with chemotherapy (gemcitabine plus nab-paclitaxel) as first-line treatment for metastatic pancreatic cancer in 61 patients. Data ran to 28 September 2026, with a median follow-up of 18.3 months.

The search term “pancreatic cancer drug daraxonrasib” is trending on Google today, 21 November 2026, in the US, the UK (number 2) and Canada (number 3).

What Did the Daraxonrasib Trial Actually Find?

What did the daraxonrasib trial actually find? Strong early signals, and clear reasons to stay cautious.

Tumors shrank or disappeared in 60.7% of the 61 patients. Complete responses, where tumors could no longer be detected on scans, happened in 8.2%, or 5 people. Disease was controlled in 90.2%, meaning tumors shrank, disappeared, or stopped growing. Median progression-free survival was 12.8 months, and the 12-month overall survival rate was 76.6%.

The US Food and Drug Administration (FDA) approved daraxonrasib on 26 August 2026 for previously treated metastatic pancreatic cancer, and the European Commission also approved it. This study tests it earlier, as a first-line treatment. A larger phase 3 trial, RASolute 303, is still needed to confirm whether the combination really beats chemotherapy alone, since this was a small, early-phase, non-randomized study with no chemotherapy-only comparison group. Side effects included rash, diarrhea, and fatigue, and only 5% stopped the drug because of them. Even so, this does not make daraxonrasib a proven first-line treatment, and it is certainly not a cure.

Pancreatic Cancer Drug Daraxonrasib: Why Does This Headline Hit So Hard?

Why does this headline hit so hard? Because pancreatic cancer has a reputation that precedes it.

Pancreatic cancer is one of the diagnoses people fear most, partly because it is so often found late and partly because survival statistics sound like a verdict without context. When a family hears “metastatic pancreatic cancer,” many hear a door closing, until a headline says tumors vanished in 1 in 12 patients. That swing is what makes this news so emotionally powerful.

Two things are happening at once. The first is the vividness effect: a concrete image, tumors disappearing on a scan, sticks far more firmly than an abstract caution like “small, non-randomized study.” The second is hope as a coping resource: not believing a cure is certain, but the sense that something might still be possible, which helps people keep showing up. The same pull shapes how families read another hopeful drug headline, the Alzheimer’s pill story.

Picture a daughter, a composite example, reading the headline in a hospital parking lot while her father has blood drawn inside. “Tumors vanished” makes her shoulders drop for the first time since the diagnosis; “small trial, needs confirming” brings the tension straight back.

What Is Scanxiety?

What is scanxiety? Scanxiety is the intense worry that builds before, during, and after medical scans, when a person or their family waits to learn whether a treatment is working or a cancer has grown.

For many families, scanxiety is the hardest part of cancer treatment. The days before a scan are filled with rehearsal: imagining the doctor’s face, replaying the last appointment, checking for results that are not there yet. Sleep gets shallow, and small aches start to look like evidence. A breakthrough headline can make it worse as well as better, because it raises the stakes of the next scan. Families call this emotional whiplash: good news that still needs confirming, a pattern familiar from Hannah Fry’s experience of living with cancer, where uncertainty itself became the thing to cope with.

Pause and ask yourself: When you read a hopeful cancer headline, what do you feel first, relief or fear that the hope will be taken away? What would change if you let both feelings be true at once?

How Do Families Process a “Breakthrough” Headline?

How do families process a “breakthrough” headline? Usually in waves, not in one calm decision. The first wave is relief, sometimes so fast it feels physical. The second wave is scrutiny: is this real, does it apply to us? The third wave is often grief, which surprises people: grief for weeks spent assuming the worst, for plans already canceled, for hope that arrived too late. A family can feel grateful and angry, hopeful and exhausted, all in the same afternoon.

Breakthrough headlines also create a quieter pressure: the feeling that you must now be optimistic. Relatives forward the article with “see, there is hope!” and the patient feels obliged to perform hopefulness they do not feel, which can make them hide their fear. Real support sounds like “this is encouraging and it is also early, and however you feel about it is allowed.” The same permission matters when grief during the holidays collides with everyone else’s insistence on cheer.

It helps to separate three questions headlines blur together: is the result real (yes, presented at a major symposium), does it apply to this patient (only their own oncology team can say), and does it change what happens next (not yet, not until phase 3 reports)? Holding those questions apart keeps hope honest.

How Can You Hold Cautious Optimism While Waiting for the Phase 3 Verdict?

How can you hold cautious optimism while waiting for the phase 3 verdict? By treating hope as something you practice in small doses, not a verdict about the future.

Cautious optimism means feeling encouraged by a real result while keeping the caveats in view. It is neither pessimism nor false positivity: the most resilient stance is flexible, able to hope for the best while preparing for harder outcomes, which protects against the crash that follows hype. Waiting itself is hard, so small rituals help: the same morning coffee, the same evening walk, the same person to call after appointments.

It also helps to widen what counts as good news: a treatment working, a week without a hospital visit, a stable scan, a family laughing together. When good news means only a breakthrough, every stable week feels like a failure. If the waiting feels overwhelming, say so to a friend, a support group, or the oncology team’s nurse. And a small gratitude practice, noticing one steady thing each day, can steady the mind.

A few things help in practice:

  • Ask one good question at the next appointment: “Does this trial apply to me, and if not, what is the closest option?”
  • Limit the 2 a.m. searching. Read updates once a day, then close the tabs. A mind stuck overthinking everything at night is not doing better research.
  • Name the feeling out loud. “I feel hopeful and scared at the same time” is more accurate, and more calming, than picking one.
  • Keep one ordinary plan. A walk, a meal, a phone call that has nothing to do with cancer.
  • Write down what the trial actually showed: the numbers, the study size, and the fact that phase 3 is still to come.

Frequently Asked Questions

Is daraxonrasib a cure for pancreatic cancer?
No. It shrank tumors in 60.7% of patients in a small early-phase trial, but the study was not randomized, and a larger phase 3 trial is needed.

What is scanxiety?
Scanxiety is the intense worry before, during, and after medical scans, while waiting to learn whether treatment is working. It is common, and it peaks just before results arrive.

How do you cope with hope and fear at the same time?
By letting both feelings exist instead of choosing one. Name them out loud, ask your oncology team one clear question, and keep one ordinary routine.

Try it on our site

If this news has stirred up a lot of feelings, these free tools may help:

Related reading: Hannah Fry on living with cancer · The Alzheimer’s pill headline, and what it really means · Why health news makes us anxious

Key Takeaways

  • Daraxonrasib plus chemotherapy shrank tumors in 60.7% of 61 patients, with complete responses in 8.2%.
  • The study was small, early-phase, and non-randomized, so phase 3 (RASolute 303) must still confirm it beats chemotherapy alone.
  • Scanxiety is normal, and breakthrough headlines can raise the stakes of the next scan.
  • Cautious optimism means holding hope and honesty together; while waiting, routines and one clear question help more than searching all night.

This article is for education only, not medical advice, therapy, or a diagnosis. If you or someone you love is struggling, please speak to a licensed professional. In the US, you can call or text 988 for the Suicide and Crisis Lifeline.

Leave a Comment